Contract Win

For immediate release 26 January 2016

Sphere Medical Holding plc

("Sphere Medical" or the "Company")

Contract Win

Sphere Medical Holding plc (AIM: SPHR.L), a leading provider of innovative monitoring and diagnostic devices for the critical care setting, announces the first sale of its Proxima system in Germany, to the University Medical Centre Göttingen.

The University Medical Centre Göttingen is a major teaching hospital with over 1,400 beds, in Lower Saxony.

Following Proxima's launch in Europe in 2015, Sphere's sales teams are also supporting further hospital evaluations at a number of sites.

Professor Michael Quintel, Director of the Department of Anaesthesiology, Emergency and Intensive Care Medicine at the University of Göttingen, said: "Proxima addresses some important issues in the management of unstable critically ill patients. We look forward to using Proxima in the University Medical Centre, improving our patient treatments and increasing efficiency."

- Ends -

For further information, please contact:

Notes for Editors

About Sphere Medical (AIM: SPHR.L)

Sphere Medical is a medical device company developing and commercialising a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.

The Company's strategy is focused on developing the Proxima (CE-marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already marketing its Proxima product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK, Germany, the Netherlands and Belgium. The Company also proposes to work with partners for the worldwide distribution of Proxima.

Proxima delivers near real time analysis of blood gases and electrolytes metabolites, at the patient's bedside. Proxima can be used on patients across a wide therapeutic range, enabling faster clinical decision making and improved patient outcomes, whilst potentially reducing costs for healthcare payers.

For further information, please visit www.spheremedical.com